Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma

Llovet, Josep M; Peña, Carol E A; Lathia, Chetan D; Shan, Michael; Meinhardt, Gerold; Bruix, Jordi (2012). Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clinical cancer research, 18(8), pp. 2290-300. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-11-2175

Full text not available from this repository. (Request a copy)

Validated biomarkers of prognosis and response to drug have not been identified for patients with hepatocellular carcinoma (HCC). One of the objectives of the phase III, randomized, controlled Sorafenib HCC Assessment Randomized Protocol (SHARP) trial was to explore the ability of plasma biomarkers to predict prognosis and therapeutic efficacy.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Visceral Surgery and Medicine > Gastroenterology

UniBE Contributor:

Wiest, Reiner

ISSN:

1078-0432

Publisher:

American Association for Cancer Research

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:40

Last Modified:

11 Jul 2018 17:14

Publisher DOI:

10.1158/1078-0432.CCR-11-2175

PubMed ID:

22374331

Web of Science ID:

000302907300020

URI:

https://boris.unibe.ch/id/eprint/16180 (FactScience: 223768)

Actions (login required)

Edit item Edit item
Provide Feedback